According to the research report titled ‘Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market - Analysis By Drug Type, Distribution Channel, By Region, and By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)’, available with Market Study Report LLC, global gastroesophageal reflux disease (GERD) therapeutics market was valued at USD 5.5 billion in 2020 and is reckoned to witness remarkable growth over the forecast period 2021-2026.
 

Increasing awareness about the disease and its symptoms, in consort with rising demand for proton pump inhibitors and acid-reducing medications are propelling worldwide gastroesophageal reflux disease (GERD) therapeutics industry growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4121730/
 

For the unversed, GERD is mainly caused by existing health conditions like obesity, and poor dietary habits. Several lifestyle factors such as shorter dinner-to-bed time, increased fat intake, and smoking & alcohol consumption have been found to be high-risk factors associated with the disease. Growing incidence of GERD in emerging countries, as well as technological advancements for prompt diagnosis are expected to stimulate industry remuneration.
 

Based on drug type, global gastroesophageal reflux disease (GERD) therapeutics industry is arrayed into H2 receptor blockers, antacids, and proton pump inhibitors (PPIs). Among these, PPI segment currently accounts for a major market share, as it is a frontline therapy for treatment of GERD. However, PPIs provide limited relief, and the treatment relapses every 6 months. Thus, H2 receptor blockers such as Vonoprazan are expected to witness substantial demand over the forecast period.
 

From a regional frame of reference, North America captures a significant chunk of the industry currently. This can be attributed to prevalence of obesity driven GERD, increasing innovations, extended life expectancy of consumers, and high per capita expenditure on healthcare in the region.
 

Prominent players in worldwide gastroesophageal reflux disease (GERD) therapeutics market are Olympus Corp., Merck & Co. Inc., Cheplapharm Arzneimittel GmbH, EndoGastric Solutions Inc., Johnson & Johnson, Ironwood Pharmaceuticals Inc., Daewoong Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eisai Co. Ltd., and Phathom Pharmaceuticals Inc.